Patented HIV-1 Integrase Inhibitors (1998-2005)
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Combination therapy, comprising at least three anti-human immunodeficiency virus (anti-HIV) drugs, has become the standard treatment of AIDS. Since 1996, highly active antiretroviral therapy (HAART) was designed to rapidly control HIV replication. It has had a significant impact on patient health and progression of AIDS in developed countries but its success has not been complete. HAART strategy still suffers from issues of patient compliance, cost, deleterious side effects and emerging drug resistance. Therefore it is logical to look for agents that inhibit different viral targets. In addition to the fusion, reverse transcription and protein formation processes, the HIV replicative cycle offers various other events that can be considered as potential targets for chemotherapeutic intervention. Amongst them integration is a key step and integrase (IN), one of the three viral enzymes, has been rapidly identified as a rational target for many years. To date, four molecules have entered in clinical trials. The present article reviews the increasing number of patents on small molecule HIV-1 integrase inhibitors in the 1998-2005 period, from the pioneer ones (discovery of selective strand transfer inhibitors) to the last patents including the actual molecules under clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., et al. (2000) · Science · doi:10.1126/science.287.5453.646 · Cited by 1,131 · cited 3×
“Expectedly, many of the inhibitors that were active in purified IN assays failed to show activity in the PIC assay since IN is inaccessible to many molecules [23, 24].”
BackgroundHeinzinger, N. K., Bukinsky, M. I., Haggerty, S. A., Ragland, A. M., Kewalramani, V, Lee, M. A., Gendelman, H. E., Ratner, L., Stevenson, M., & Emerman, M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.15.7311 · Cited by 854
Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase
Davies, J. F., Hostomska, Z., Hostomsky, Z., Jordan, S. R., & Matthews, D. A. (1991) · Science · doi:10.1126/science.1707186 · Cited by 570
Bukrinsky, M. I., Sharova, N., McDonald, T. L., Pushkarskaya, T., Tarpley, W. G., & Stevenson, M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.13.6125 · Cited by 451
Bailly, F., & Cotelle, P. (2005) · Current Medicinal Chemistry · doi:10.2174/0929867054367239 · Cited by 71
Self-citation
Cited by
DU, L., ZHAO, Y.-X., YANG, L.-M., ZHENG, Y.-T., TANG, Y., SHEN, X., & JIANG, H.-L. (2008) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2008.00863.x · Cited by 22
Combination therapies for traumatic brain injury: prospective considerations
Margulies, S. S., & Hicks, R. (2009) · Journal of Neurotrauma · doi:10.1089/neu.2008-0794 · Cited by 22
Metadata
- Authors
- Cotelle, P.
- Venue
- Recent Patents on Anti-Infective Drug Discovery
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2006-01-01
- Volume
- 1
- Issue
- 1
- Pages
- 1-15
- ISSN
- 1574-891X (ISSN-L)
- OpenAlex
- W2017173005
- Cited by
- 47
- References
- 5
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Patented HIV-1 Integrase Inhibitors (1998-2005). https://app.cochat.ai/papers/10.2174/157489106775244082
- The paper
- Cotelle, P. (2006). Patented HIV-1 Integrase Inhibitors (1998-2005). Recent Patents on Anti-Infective Drug Discovery. https://doi.org/10.2174/157489106775244082
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.